Mads Krogsgaard Thomsen/LinkedIn
Dec 16, 2025, 16:34
Mads Krogsgaard Thomsen on Novo Nordisk Haemophilia Foundation’s Support for Haemoglobinopathies
Mads Krogsgaard Thomsen, CEO at Novo Nordisk Foundation, shared on LinkedIn:
”Haemophilia and other blood disorders like sickle cell disease and thalasaemia are chronic, debilitating diseases.
As is often the case, global health inequity is very pronounced, with under-diagnosis, under-treament and poor outcomes as a result in many low and middle income countries.
It is therefore a pleasure to announce that Novo Nordisk Foundation is stepping up, both in absolute funding terms, and in adding the haemoglobinopathy disorders to our support to the Novo Nordisk Haemophilia and Haemoglobinopathies Foundation in these areas.”
Read the full announcement here.

Stay updated with Hemostasis Today.
-
Nov 15, 2026, 23:44Pablo César Spada: Prevention of Venous Thromboembolism After Total Hip or Knee Replacement
-
Nov 15, 2026, 23:30Eshal Amir: Factor XI Inhibitors in AFib and Aortic Mortality Trends
-
Nov 15, 2026, 23:19Hamza Bashir: Adding Endovascular Therapy to Anticoagulation Cuts Moderate-to-Severe PTS in Half
-
Nov 15, 2026, 23:06Lanre Tunji-Ajayi: 2 Days of Deliberative Dialogue Hosted by the Network of Rare Blood Disorder Organizations
-
Nov 15, 2026, 23:00Fanny Delettre: Looking Back at Volunteer Blood Donor Friends Day
-
Nov 15, 2026, 20:56Victoria Adedoyin Adisa-Thomas: What I Learned About SCD During My Genetic Counselling Rotation
-
Nov 15, 2026, 20:55Martin Holst Lange: One Step Closer to a Potential New Treatment for Sickle Cell Disease
-
Nov 15, 2026, 20:53Bontha Babu: Health-Related Quality of Life Among Adults with Sickle Cell Disease in India
-
Nov 15, 2026, 20:52Miguel Ángel Herrera Rojas: A First-Line ITP Approach Presented at ASH in 2013 Now Reflected in the 2026 Guidelines